Proline homozygosity in codon 72 of TP53 is a factor of susceptibility to nasopharyngeal carcinoma in Tunisia

Cancer Genetics and Cytogenetics

Volumn 178, Issue 2, 2007, Pages 89-93

  Hadhri Guiga, Boutheina ^a   Toumi, Nabil ^b   Khabir, Abdelmajid ^b   Sellami Boudawara, Tahia ^b   Ghorbel, Abdelmoonem ^b   Daoud, Jamel ^b   Frikha, Mounir ^b   Gargouri, Ali ^a   Mokdad Gargouri, Raja ^a  

^a CENTRE DE BIOTECHNOLOGIE DE SFAX   (Tunisia)

^b HABIB BOURGUIBA HOSPITAL   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

PROLINE; PROTEIN P53;

ADULT; AGE DISTRIBUTION; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD SAMPLING; CANCER RISK; CANCER SUSCEPTIBILITY; CODON; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HIGH RISK POPULATION; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NASOPHARYNX CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SEX DIFFERENCE; TUNISIA;

ADOLESCENT; ADULT; AGED; APOPTOSIS; CARCINOMA; CARCINOMA, SQUAMOUS CELL; CHILD; CODON; HUMANS; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROLINE; REFERENCE VALUES; TUMOR SUPPRESSOR PROTEIN P53; TUNISIA;

EID: 35348991682     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2007.05.013     Document Type: Article

References (38)

1. Ho J.H.C. An epidemiologic and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 4 (1978) 182-198
2. McDermott A.L., Dutt S.N., and Watkinson J.C. The etiology of nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci 26 (2001) 82-90
3. Yu M.C., and Yuan J.M. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 12 (2002) 421-429
4. Spano J.P., Busson P., Atlan D., Bourhis J., Pignon J.P., Esteban C., and Armand J.P. Nasopharyngeal carcinomas: an update. Eur J Cancer 39 (2003) 2121-2135
5. Lo K.W., To K.F., and Huang D.P. Focus on nasopharyngeal carcinoma. Cancer Cell 5 (2004) 423-428
6. Lo K.W., and Huang D.P. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol 12 (2002) 451-462
7. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 12 (2002) 431-441
8. Levine A.J. p53: the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
9. Szymańska K., and Hainaut P. TP53 and mutations in human cancer. Acta Biochim Pol 50 (2003) 231-238
10. Vousden K.H. Activation of the p53 tumor suppressor protein. Biochim Biophys Acta 1602 (2002) 47-59
11. Effert P., McCoy R., Abdel-Hamid M., Flynn K., Zhang Q., Busson P., Tursz T., Liu E., and Raab-Traub N. Alterations of the p53 gene in nasopharyngeal carcinoma. J Virol 66 (1992) 3768-3775
12. Sun Y., Hegamyer G., Cheng Y.J., Hildesheim A., Chen J.Y., Chen I.H., Cao Y., Yao K.T., and Colburn N.H. An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc Natl Acad Sci U S A 89 (1992) 6516-6520
13. Khabir A., Sellami A., Sakka M., Ghorbel A.M., Daoud J., Frikha M., Drira M.M., Busson P., and Jlidi R. Contrasted frequencies of p53 accumulation in the two age groups of North African nasopharyngeal carcinomas. Clin Cancer Res 6 (2000) 3932-3936
14. Pietsch E.C., Humbey O., and Murphy M.E. Polymorphism in the p53 pathway. Oncogene 25 (2006) 602-611
15. Ara S., Lee P.S., Hansen M.F., and Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res 18 (1990) 4961
16. De la Calle-Martin O., Fabregat V., Romero M., Soler J., Vives J., and Yague J. AccII polymorphism of the p53 gene. Nucleic Acids Res 18 (1990) 4963
17. Dumont P., Leu J.I., Della Pietra III A.C., George D.L., and Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 3 (2003) 357-365
18. Shen H., Solari A., Wang X., Zhang Z., Xu Y., Wang L., Hu X., Guo J., and Wei Q. P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. Oncol Rep 11 (2004) 1115-1120
19. Bonafe M., Ceccarelli C., Farabegoli F., Santini D., Taffurelli M., Barbi C., Marzi E., Trapassi C., Storci G., Olivieri F., and Franceschi C. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res 9 (2003) 4860-4864
20. Buyru N., Tigli H., and Dalay N. P53 codon 72 polymorphism in breast cancer. Oncol Rep 10 (2003) 711-714
21. Dong M., Nio Y., Yamasawa K., Toga T., Yue L., and Harada T. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer. J Surg Oncol 82 (2003) 111-120
22. Wu W.J., Kakehi Y., Habuchi T., Kinoshita H., Ogawa O., Terachi T., Huang C.H., Chiang C.P., and Yoshida O. Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers. Jpn J Cancer Res 86 (1995) 730-736
23. Storey A., Thomas M., Kalita A., Harwood C., Gardiol D., Mantovani F., Breuer J., Leigh I.M., Matlashewski G., and Banks L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393 (1998) 229-234
24. Granja F., Morari J., Morari E.C., Correa L.A., Assumpcao L.V., and Ward L.S. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer Lett 210 (2004) 151-157
25. Wang Y.C., Lee H.S., Chen S.K., Chang Y.Y., and Chen C.Y. Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. Eur J Cancer 35 (1999) 226-230
26. Yu M.W., Yang S.Y., Chiu Y.H., Chiang Y.C., Liaw Y.F., and Chen C.J. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology 29 (1999) 697-702
27. Mabrouk I., Baccouche S., El-Abed R., Mokdad-Gargouri R., Mosbah A., Said S., Daoud J., Frikha M., Jlidi R., and Gargouri A. No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci 1010 (2003) 764-770
28. Fan R., Wu M.T., Miller D., Wain J.C., Kelsey K.T., Wiencke J.K., and Christiani D.C. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 9 (2000) 1037-1042
29. Birgander R., Själander A., Zhou Z., Fan C., Beckman L., and Beckman G. p53 polymorphisms and haplotypes in nasopharyngeal cancer. Hum Hered 46 (1996) 49-54
30. Yung W.C.W., Ng M.H., Sham J.S.T., and Choy D.T.K. p53 codon 72 polymorphism in nasopharyngeal carcinoma. Cancer Genet Cytogenet 93 (1997) 181-182
31. Tsai M.H., Lin C.D., Hsieh Y.Y., Chang F.C., Tsai F.J., Chen W.C., and Tsai C.H. Prognostic significance of the proline form of p53 codon 72 polymorphism in nasopharyngeal carcinoma. Laryngoscope 112 (2002) 116-119
32. Tiwawech D., Srivatanakul P., Karaluk A., and Ishida T. The p53 codon 72 polymorphism in Thai nasopharyngeal carcinoma. Cancer Lett 198 (2003) 69-75
33. Baccouche S., Mabrouk I., Said S., Mosbah A., Jlidi R., and Gargouri A. A more accurate detection of codon 72 polymorphism and LOH of the TP53 gene. Cancer Lett 189 (2003) 91-96
34. Kawaguchi H., Ohno S., Araki K., Miyazaki M., Saeki H., Watanabe M., Tanaka S., and Sugimachi K. p53 polymorphism in human papillomavirus-associated esophageal cancer. Cancer Res 60 (2000) 2753-2755
35. Shen H., Liu Z., Strom S.S., Spitz M.R., Lee J.E., Gershenwald J.E., Ross M.I., Mansfield P.F., Duvic M., Ananthaswamy H.N., and Wei Q. p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. J Invest Dermatol 121 (2003) 1510-1514
36. de Oliveira W.R., Rady P.L., Grady J., Hughes T.K., Neto C.F., Rivitti E.A., and Tyring S.K. Association of p53 arginine polymorphism with skin cancer. Int J Dermatol 43 (2004) 489-493
37. Soulitzis N., Sourvinos G., Dokianakis D.N., and Spandidos D.A. P53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 179 (2002) 175-183
38. Suzuki K., Matsui H., Ohtake N., Nakata S., Takei T., Nakazato H., Okugi H., Koike H., Ono Y., Ito K., Kurokawa K., and Yamanaka H. A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J Biomed Sci 10 (2003) 430-435